PARIS--(BUSINESS WIRE)-- Regulatory News: L'Assemblée générale annuelle ordinaire et extraordinaire des actionnaires d'Eutelsat Communications (ISIN : FR0010221234 - Euronext Paris / London Stock Exchange : ETL) réunie ce jour a approuvé l’ensemble des résolutions proposées, notamment : L’approbation des comptes ; Renouvellement du mandat de Madame Eva Berneke en qualité d’administratrice ; Ratification de la nomination de la société Hanwha Systems UK Limited (représentée par Mme Joo-Yong Chung) en qualité d’administratrice ; Nomination d’Ernst & Young et Autres et Forvis Mazars ...
PARIS--(BUSINESS WIRE)-- Regulatory News: Eutelsat Group (ISIN : FR0010221234 - Euronext Paris / London Stock Exchange : ETL) annonce la signature d'un nouvel accord pluriannuel avec Q-KON, acteur majeur dans la fourniture de solutions et de services satellitaires, afin d'étendre les services satellitaires en orbite terrestre basse (LEO) à l'ensemble de l'Afrique subsaharienne. Ce nouvel accord permettra d’accélérer le déploiement de services de connectivité à haut débit et à faible latence pour les entreprises et les communautés situées dans les zones mal desservies du continent africain, n...
PARIS--(BUSINESS WIRE)-- Regulatory News: Eutelsat Group (ISIN: FR0010221234 - Euronext Paris / London Stock Exchange: ETL), announces a new multi-year agreement with Q-KON, a leading satellite solutions and services provider, to expand Low Earth Orbit (LEO) satellite services across Sub-Saharan Africa. The agreement will further accelerate the delivery of high-speed, low-latency connectivity to specialized and underserved businesses and communities, particularly in Southern Africa. The expanded agreement with Q-KON builds on the successful 2023 incorporation of Eutelsat’s OneWeb LEO satel...
>Opinion Sous-performance réitérée, OC ajusté à 7 CHF (vs 12 CHF) - Le titre ams OSRAM est en baisse de ~10% depuis la publication T3 24 (07/11), après des objectifs 2027 ressortis ~7% en dessous des attentes au niveau de l’EBITDA, une visibilité limitée à CT (T1 25 attendu ‘faible’) et un FCF décevant (-35 M€ en excluant l’effet d’un prépaiement vs un consensus à -17 M€). Cela nous conduit à revoir en baisse nos prévisions de BPA 2026/27e de ~45/32% et notre OC à 7 C...
>Underperform rating maintained, target price adjusted to CHF 7 (vs CHF 12) - ams OSRAM’s share price has shed ~10% since the Q3 24 release (07/11), after the 2027 guidance came in ~7% short of expectations at the EBITDA level, with limited visibility in the short term (Q1 25 expected to be ‘weak’) and disappointing FCF (-€ 35m excluding the effect of a prepayment vs a consensus of -€ 17m). On this basis, we have downgraded our 2026-2027 EPS estimates by ~45/32% and c...
AMS Osram has released Q3/24 results that were in line with management's guidance. Despite a decline in y-o-y revenues, adjusted EBITDA and the adjusted EBITDA margin improved, boosted by one-off payments. Consequently, cash generation strengthened significantly. Both net debt and net leverage declined sequentially. Liquidity improved, and remains at a comfortable level. The near-term outlook is soft, given the weakness in the company's end-markets.
>Rare diseases are a growth driver - Recordati reported on Friday during trading its figures for Q3 2024. Sales over the period are 2.8% below forecasts at € 557.4m (+9% y-o-y). We highlight: i/ growth momentum still driven by the rare diseases segment (+14.5% cc) for 9M, with business continuing to benefit from endocrinology (+36%) and oncology (+17%); ii/ growth in the SPC franchise is still robust at 9% (+6.5% cc), but more impacted than expected by the Cough&Cold ...
>Les maladies rares en locomotive de la croissance - Recordati a publié vendredi en séance ses chiffres au titre du T3 2024. Les ventes sur la période ressortent 2.8% inférieures aux attentes à 557.4 M€ (+9% yoy). Nous soulignons i/ une dynamique de croissance toujours tirée par le segment des maladies rares (+14,5% tcc) sur les 9 premiers mois, l'activité continue de bénéficier de l'endocrinologie (+36%) et de l'oncologie (+17%), ii/ la croissance de la franchise SPC...
In today's Morning Views publication we comment on developments of the following high yield issuers: Nexans, Recordati, TeamSystem, Stada, CMA CGM, Nexi, Vedanta Resources, Fedrigoni, Modulaire, TI Fluid Systems, Iceland Foods, United Group, Standard Profil, Selecta, Italmatch Chemicals
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY...
In today's Morning Views publication we comment on developments of the following high yield issuers: AMS Osram, Sappi, Ahlstrom, Trivium, Verisure, Rolls-Royce, Air France-KLM, Bombardier, Constellium, Cirsa, Kem One, Arxada, Borr Drilling, Maxeda, NewDay, Flora Food Group (formerly Upfield), Banijay
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.